Influenza virosomes enhance class I restricted CTL induction through CD4+ T cell activation

Vaccine

Volumn 22, Issue 5-6, 2004, Pages 714-723

  Schumacher, Reto ^a   Adamina, Michel ^a   Zurbriggen, Rinaldo ^b   Bolli, Martin ^a   Padovan, Elisabetta ^a   Zajac, Paul ^a   Heberer, Michael ^a   Spagnoli, Giulio C ^a,c  

^a UNIVERSITY OF BASEL   (Switzerland)

^b Pevion Biotech Ltd   (Switzerland)

^c ZLF   (Switzerland)

Author keywords

Adjuvance; CTL; T helper 1; Virosomes

Indexed keywords

ADJUVANT; CD4 ANTIGEN; CYTOKINE; EPITOPE; HLA ANTIGEN CLASS 1; LIPOSOME; MELAN A; VIROSOME;

ANTIGENICITY; ARTICLE; CELL STIMULATION; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DRUG EFFECT; DRUG MECHANISM; DRUG SPECIFICITY; HUMAN; HUMAN CELL; IMMUNOPOTENTIATION; IN VITRO STUDY; INFLUENZA VIRUS; INTERMETHOD COMPARISON; LYMPHOCYTE CULTURE; MELANOMA; NORMAL HUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN INDUCTION; T LYMPHOCYTE ACTIVATION; TH1 CELL;

EID: 1642452611     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2003.08.019     Document Type: Article

References (26)

1. Singh M., O'Hagan D. Advances in vaccine adjuvants. Nature Biotechnol. 17:1999;1075-1081.
2. Raychaudhuri S., Rock K.L. Fully mobilizing host defense: building better vaccines. Nature Biotechnol. 16:1998;1025-1031.
3. Seder R.E., Hill A.V.S. Vaccines against intracellular infections requiring cellular immunity. Nature. 406:2000;793-798.
4. Moingeon P., Haensler J., Lindberg A. Towards the rational design of Th1 adjuvants. Vaccine. 19:2001;4363-4372.
5. Glück R., Mischler R., Finkel B., Que J.U., Scarpa B., Cryz S.J. Jr. Immunogenicity of new virosome influenza vaccine in elderly people. Lancet. 344:1994;160-163.
6. Glück R., Metcalfe I.C. Novel approaches in the development of immunopotentiating reconstituted influenza virosomes as efficient antigen carrier system. Vaccine. 21:2003;611-615.
7. Arkema A., Huckriede A., Schoen P., Wilschut J., Daemen T. Induction of cytotoxic T lymphocyte activity by fusion-active peptide-containing virosomes. Vaccine. 18:2000;1327-1333.
8. Hunziker I., Grabscheid B., Zurbriggen R., Glück R., Pichler W.J., Cerny A. In vitro studies of core peptide-bearing immunopotentiating reconstituted influenza virosomes as a non-live prototype vaccine against hepatitis C virus. Int. Immunol. 14:2002;615-626.
9. Bungener L., Huckriede A., Wilschut J., Daemen T. Delivery of protein antigens to the immune system by fusion-active virosomes: a comparison with liposomes and ISCOMS. Biosci. Rep. 22:2002;323-338.
10. Chikh G., Kong S., Bally M.B., Meunier J.C., Schutze-Redelmeier M.-P. Efficient delivery of Antennapedia homeodomain fused CTL epitope with liposomes into dendritic cells results in the activation of CD8+ T cells. J. Immunol. 167:2001;6462-6470.
11. Machy P., Serre K., Leserman L. Class I-restricted presentation of exogenous antigen acquired by Fc gamma receptor-mediated endocytosis regulated in dendritic cells. Eur. J. Immunol. 30:2000;848-857.
12. Skehel J.J., Schild G.C. The polypeptide composition of influenza A viruses. Virology. 44:1971;396-408.
13. Guesdon J.L., Avrameas S. An immunoenzymatic method for measuring low concentrations of antigens by single radial diffusion. Immunochemistry. 11:1974;595-598.
14. Filgueira L., Zuber M., Juretic A.et al. Differential effects of interleukin-2 and CD3 triggering on cytokine gene transcription and secretion in cultured tumor infiltrating lymphocytes. Cell Immunol. 150:1993;205-218.
15. Oertli D., Marti W.R., Zajac P.et al. Rapid induction of specific cytotoxic T lymphocytes against melanoma associated antigens by a recombinant vaccinia virus expressing multiple immunodominant epitopes and costimulatory molecules in vivo. Hum. Gene Ther. 13:2002;569-575.
16. Chaux P., Vantomme V., Coulie P., Boon T., van der Bruggen P. Estimation of the frequencies of anti MAGE-3 cytolytic T-lymphocyte precursors in blood from individuals without cancer. Int. J. Cancer. 77:1998;538-542.
17. Haight FA. Handbook of the Poisson distribution. New York: Wiley; 1967.
18. Saurwein-Teissl M., Zisterer K., Schmitt T.L., Glück R., Cryz S., Grubeck-Loebenstein B. Whole virus influenza vaccine activates dendritic cells (DC) and stimulates cytokine production by peripheral blood mononuclear cells (PBMC) while subunit vaccines support T cell proliferation. Clin. Exp. Immunol. 114:1998;271-276.
19. Qin S., Rottman J.B., Myers P.et al. The chemokine receptors CXCR3 and CCR5 mark subsets of T cells associated with certain inflammatory reactions. J. Clin. Invest. 101(4):1998;746-754.
20. Salio M., Shepherd D., Dunbar P.R.et al. Mature dendritic cells prime functionally superior Melan-A-specific CD8+ lymphocytes as compared with nonprofessional APC. J. Immunol. 167:2001;1188-1197.
21. Glück R. Adjuvant activity of immunopotentiating reconstituted influenza virosomes (IRIVs). Vaccine. 17:1999;1782-1787.
22. Lanzavecchia A. Licence to kill. Nature. 393:1998;413-414.
23. Schoenberger S., Toes R., Van der Voort E., Offringa R., Melief C. T-cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions. Nature. 393:1998;480-483.
24. Ridge J.P., Di Rosa F., Matzinger P. A conditioned dendritic cell can be a temporal bridge between a CD4+ T-helper and a T-killer cell. Nature. 393:1998;474-478.
25. Bacon A., Caparros-Wanderley W., Zadi B., Gregoriadis G. Induction of a cytotoxic T lymphocyte (CTL) response by plasmid DNA delivered via Lipodine liposomes. J. Liposome Res. 12:2002;173-183.
26. Gregoriadis G., Bacon A., Caparros-Wanderley W., McCormack B. A role for liposomes in genetic vaccination. Vaccine. 20(Suppl 5):2002;B1-B9.